Literature DB >> 25954498

Optimizing the use of thiopurines in inflammatory bowel disease.

Rishi M Goel1, Paul Blaker2, Alex Mentzer2, Steven C M Fong2, Anthony M Marinaki3, Jeremy D Sanderson2.   

Abstract

Immunomodulator drugs, of which thiopurines can be considered the backbone, are widely used in the treatment of inflammatory bowel disease. They have been shown to be highly effective and safe; however, a significant proportion of patients are deemed to have a poor response or suffer adverse reactions. Knowing how to monitor and optimize thiopurine therapy in these scenarios is crucial to effective management. We discuss the metabolism of thiopurines, the use of enzyme/metabolite testing to guide treatment, as well as strategies to circumvent toxicity and side effects, such as allopurinol coprescription. The indications, use in pregnancy, safety profile and duration of thiopurine therapy are also discussed.

Entities:  

Keywords:  Crohn’s disease; azathioprine; drugs; gastroenterology; inflammatory bowel disease; thiopurines; ulcerative colitis

Year:  2015        PMID: 25954498      PMCID: PMC4416969          DOI: 10.1177/2040622315579063

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  50 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.

Authors:  X Roblin; F Serre-Debeauvais; J-M Phelip; J-L Faucheron; G Hardy; A Chartier; F Helluwaert; G Bessard; B Bonaz
Journal:  Aliment Pharmacol Ther       Date:  2005-04-01       Impact factor: 8.171

3.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.

Authors:  C Cuffari; S Hunt; T Bayless
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 4.  Are we using and monitoring thiopurines and biologics optimally?

Authors:  Peter M Irving
Journal:  Dig Dis       Date:  2014-06-23       Impact factor: 2.404

5.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

6.  Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.

Authors:  Yvette Leung; Miles P Sparrow; Marc Schwartz; Stephen B Hanauer
Journal:  J Crohns Colitis       Date:  2009-03-17       Impact factor: 9.071

7.  Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease.

Authors:  Heimo H Wenzl; Christian Primas; Gottfried Novacek; Alexander Teml; Anna Öfferlbauer-Ernst; Christoph Högenauer; Harald Vogelsang; Wolfgang Petritsch; Walter Reinisch
Journal:  Dig Dis Sci       Date:  2014-11-08       Impact factor: 3.199

8.  Azathioprine and breastfeeding: is it safe?

Authors:  A Sau; S Clarke; J Bass; A Kaiser; A Marinaki; C Nelson-Piercy
Journal:  BJOG       Date:  2007-01-25       Impact factor: 6.531

9.  Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.

Authors:  R B Gearry; M L Barclay; M J Burt; J A Collett; B A Chapman; R L Roberts; M A Kennedy
Journal:  Aliment Pharmacol Ther       Date:  2003-08-15       Impact factor: 8.171

10.  The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis.

Authors:  Sukhdev Chatu; Venkataraman Subramanian; Sonia Saxena; Richard C G Pollok
Journal:  Am J Gastroenterol       Date:  2013-12-10       Impact factor: 10.864

View more
  19 in total

1.  Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels - a review of routine practice.

Authors:  Naomi Jessurun; Eugène P van Puijenbroek; Leila S Otten; Oenone Mikes; Annemieke Vermeulen Windsant; Rob J van Marum; Koen Grootens; Hieronymus J Derijks
Journal:  Br J Clin Pharmacol       Date:  2017-01-29       Impact factor: 4.335

Review 2.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 3.  Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review.

Authors:  Shivani Deswal; Anshu Srivastava
Journal:  J Clin Exp Hepatol       Date:  2017-02-06

4.  The association between pre-colectomy thiopurine use and risk of neoplasia after ileal pouch anal anastomosis in patients with ulcerative colitis or indeterminate colitis: a propensity score analysis.

Authors:  Maia Kayal; Alexa Riggs; Michael Plietz; Sergey Khaitov; Patricia Sylla; Alexander J Greenstein; Noam Harpaz; Steven H Itzkowitz; Shailja C Shah
Journal:  Int J Colorectal Dis       Date:  2021-09-27       Impact factor: 2.571

Review 5.  Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.

Authors:  Ji Young Chang; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2019-07-09       Impact factor: 3.487

Review 6.  Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease.

Authors:  Yaron Ilan
Journal:  Clin Transl Immunology       Date:  2016-01-29

Review 7.  How I treat my inflammatory bowel disease-patients with thiopurines?

Authors:  Berrie Meijer; Chris Jj Mulder; Adriaan A van Bodegraven; Nanne K H de Boer
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

8.  Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD.

Authors:  Brigitte Moreau; Pierre Clement; Yves Theoret; Ernest G Seidman
Journal:  Therap Adv Gastroenterol       Date:  2017-10-11       Impact factor: 4.409

Review 9.  Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

Authors:  Carla J Gargallo-Puyuelo; Viviana Laredo; Fernando Gomollón
Journal:  Front Med (Lausanne)       Date:  2021-07-16

10.  Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Authors:  Mark A Samaan; Polychronis Pavlidis; Jonathan Digby-Bell; Emma L Johnston; Angad Dhillon; Ramesh Paramsothy; Abisoye O Akintimehin; Lucy Medcalf; Guy Chung-Faye; Patrick DuBois; Ioannis Koumoutsos; Nick Powell; Simon H C Anderson; Jeremy Sanderson; Bu' Hussain Hayee; Peter M Irving
Journal:  Frontline Gastroenterol       Date:  2017-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.